Involving Virus Or Bacteriophage Patents (Class 435/5)
  • Patent number: 9765309
    Abstract: Presented herein are polymerase enzymes for improved incorporation of nucleotide analogs, in particular nucleotides which are modified at the 3? sugar hydroxyl, as well as methods and kits using the same.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: September 19, 2017
    Assignee: ILLUMINA, INC.
    Inventors: Cheng-Yao Chen, Erin Bomati, Molly He
  • Patent number: 9764023
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: September 19, 2017
    Assignee: Academish Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Melief
  • Patent number: 9765115
    Abstract: The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized and can be used to attenuate or inhibit metastasis in solid cancer tumors.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 19, 2017
    Assignee: Board of Supervisors of Louisiana State University acting on behalf of the University of Louisiana at Monroe
    Inventor: Girish V. Shah
  • Patent number: 9765155
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: September 19, 2017
    Assignee: City of Hope
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Patent number: 9758818
    Abstract: Disclosed herein is a polymerase chain reaction (PCR)-based method for detecting an insertion/deletion variant, as compared with a reference sequence, in a selected region of a target gene in a sample. The target gene has a template strand and a coding strand complementary to the template strand. The method uses a primer set that includes a blocking primer, and a forward primer. The blocking primer and the forward primer are partially overlapping and have different melting temperatures, and the 3?-end of the blocking primer is modified to prevent the extension of the blocking primer during the PCR. Accordingly, under specific PCR conditions, the presence of the PCR product is indicative of the presence of an insertion/deletion mutation in the selected region, and the absence of the PCR product is indicative of the absence of an insertion/deletion mutation in the selected region.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: September 12, 2017
    Inventors: Jr-Kai Huang, Chi-Kuan Chen, Tao-Yeuan Wang
  • Patent number: 9751913
    Abstract: A genetically modified cowpea mosaic virus (CPMV) protein capsid serves as a scaffold for metal nanoparticles, preferably gold nanospheres, of 15 nm to 35 nm, creating plasmonic nanoclusters. The self-assembled nanoclusters gave rise to a 10-fold surface-averaged enhancement of the local electromagnetic field. Other viral capsids or virus-like proteins may also serve as such scaffolds.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 5, 2017
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Banahalli R. Ratna, Carissa M. Soto, Ronald W. Rendell, Jake Fontana, Jeffrey R. Deschamps
  • Patent number: 9753034
    Abstract: A process for the identification of compounds with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins which comprises selecting those compounds which are able to: a) form a hydrogen bonding interaction in which the compound accepts a hydrogen bond from the sidechain NH2 group of the asparagine residue found at: BRD-2 BRD-2 BRD-3 BRD-3 BRD-4 BRD-4 BD1 BD2 BD1 BD2 BD1 BD2 ASN156 ASN429 ASN116 ASN391 ASN140 ASN433 or b) accept a water-mediated hydrogen bond in which the compound accepts a hydrogen bond from a water that is itself hydrogen-bonded to the sidechain hydroxyl of the tyrosine residue found at BRD-2 BRD-2 BRD-3 BRD-3 BRD-4 BRD-4 BD1 BD2 BD1 BD2 BD1 BD2 TYR113 TYR386 TYR73 TYR348 TYR97 TYR390 and c) which are also able to form a Van der Waals interaction with a lipophi
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 5, 2017
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Paul Bamborough, Chun-Wa Chung
  • Patent number: 9753038
    Abstract: This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against CAPRIN-1 having the amino acid sequence shown in any even-numbered SEQ ID NO of SEQ ID NOs: 2 to 30 in the Sequence Listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of CAPRIN-1 in a sample of a cancer patient in order to determine the administration of a CAPRIN-1-targeting drug to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-CAPRIN-1 antibody.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: September 5, 2017
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Takayoshi Ido, Fumiyoshi Okano
  • Patent number: 9744197
    Abstract: Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is a lactic acid producing bacteria. In one embodiment, the process comprises inoculating a lactobacillus fermentation medium with lactic acid producing bacterial cells, harvesting the lactic acid producing bacterial cells at mid to late log phase, concentrating the lactic acid producing bacterial cells, and preserving the lactic acid producing bacterial cells at a concentration of at least 5×109 cfu/ml.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: August 29, 2017
    Assignee: MICROBIOS INC.
    Inventors: Matthew Ryan Garner, Joseph F. Flint
  • Patent number: 9744228
    Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: August 29, 2017
    Assignee: Norvartis AG
    Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
  • Patent number: 9746407
    Abstract: The present invention relates to a method for detecting molecular interactions in a solution. In particular, the present invention relates to a method for detecting interactions between two substances that are likely to interact with one another. The present invention can be used in particular in the field of scientific research and in the field of medical analysis.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: August 29, 2017
    Assignee: Biofilm Control
    Inventors: Thierry Bernardi, Pascal Mayer, Jérôme Groelly
  • Patent number: 9738941
    Abstract: Methods for screening a multiplicity of respiratory pathogens by isolating nucleic acids from a sample include isolating a nucleic acid from a sample and using solid phase amplification with forward primers SEQ ID NOs: 1 to 16 or 33 or 35 and corresponding reverse primers SEQ ID NOs: 17 to 32 or 34 or 36 along with probes to generate amplicons. The method further includes employing bead sets which are homogenous with respect to bead size and optionally with respect to the intensity of the label. Binding of a particular amplicon to a subset of beads determines the identity of the respiratory pathogen.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: August 22, 2017
    Assignee: Genera Biosystems Limited
    Inventors: Karl Frederick Poetter, Nick Vandegraaff
  • Patent number: 9738888
    Abstract: Disclosed is a process for retrieval of nucleotide sequence. The process includes mixing iron chloride tetrahydrate with iron (III) chloride hexahydrate in solution; adding ammonium hydroxide to the mixture and stirring to form maghemite nanoparticles; stirring the maghemite nanoparticles in a solution with an inorganic acid, a surfactant and a monomer precursor of a conducting polymer; initiating polymerization of the monomer by adding the inorganic acid and an oxidizing agent to the stirred solution and further stirring to yield Polyaniline/maghemite nanocomposites; adding the nanocomposites to an first aqueous solution of the nucleotide sequence and stirring so as to electrostatically interact the nanocomposites with the nucleotide sequence; and weakening the electrostatic interaction between the nanocomposite and the nucleotide sequence to recover the nanocomposite independently of the nucleotide sequence.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: August 22, 2017
    Inventors: Juan Carlos Medina-Llamas, Alicia Elizabeth Chávez-Guajardo, Cesar Augusto Souza de Andrade, Kleber Goncalves Bezerra Alves, Celso Pinto de Melo
  • Patent number: 9740946
    Abstract: The present invention relates to a medical data processing method for identifying an entity of the nervous system, in particular the brain, of a patient, wherein the method is designed to be executed by a computer and comprises the following steps: a) acquiring target connectivity data comprising target connectivity information about the probability of a target entity being connected to other entities of the nervous system; b) acquiring candidate connectivity data comprising candidate connectivity information about the probability of at least one candidate entity being connected to other entities of the nervous system; and c) determining similarity data for each of the at least one candidate entities on the basis of the candidate connectivity data and the target connectivity data, wherein the similarity data comprise similarity information about the similarity between the candidate entity and the target entity.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: August 22, 2017
    Assignee: Brainlab AG
    Inventors: Bálint Varkuti, Rainer Lachner
  • Patent number: 9734901
    Abstract: The present invention provides a display device including a nonvolatile memory circuit to which data can be added without increasing the number of manufacturing steps, and an electronic appliance using the display device. A display device of the present invention has a memory circuit that includes a memory element with a simple structure in which an organic compound layer is interposed between a pair of conductive layers. According to the present invention having the above mentioned structure, a display device having a nonvolatile memory circuit to which data can be added can be provided without increasing the number of manufacturing steps.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: August 15, 2017
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Yasuko Watanabe, Yasuyuki Arai, Hiroko Abe, Yuji Iwaki, Mikio Yukawa, Shunpei Yamazaki
  • Patent number: 9732384
    Abstract: Described herein is a device including a nanotube disposed within a support material. The nanotube has one or more sidewall electrodes, two nanomembranes, and an enzyme. One of the nanomembrane is in direct contact with at least a portion of one sidewall electrode. The other nanomembrane form a nanochannel, nanopore, or a combination thereof, and can alter one or more of a molecular composition, a dimension, or a property thereof in response to electrical stimuli.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: August 15, 2017
    Assignee: LUX BIO GROUP, INC.
    Inventor: Gordon Holt
  • Patent number: 9724356
    Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: August 8, 2017
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert Emil Hodge, Jeffrey Douglas Webster
  • Patent number: 9721062
    Abstract: The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treatment regime. The methods may also be used to evaluate protein and/or metabolite levels that correlate with such clinical conditions. The methods are also of use to ascertain the probability outcome for a patient's particular prognosis.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 1, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: John Zachary Sanborn, David Haussler
  • Patent number: 9719084
    Abstract: A method is provided for generating RNA nanoparticles having modified nucleotides and/or having increased nuclease resistance where the RNA nanoparticles are formed cotranscriptionally by T7 RNA polymerase in the presence of manganese ions.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: August 1, 2017
    Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, The Regents of the University of California
    Inventors: Bruce A. Shapiro, Kirill A. Afonin, Maria L. Kireeva, Mikhail Kashlev, Luc Jaeger, Wade W. Grabow
  • Patent number: 9709566
    Abstract: The chromatography method of the present invention includes (a) developing a complex of a test substance and a labeling substance modified with a first binding substance bindable to the test substance, onto an insoluble carrier, (b) causing the complex to be trapped in a reaction site on the insoluble carrier which contains a second binding substance bindable to the test substance or a substance exhibiting binding properties to the first binding substance, (c) washing the insoluble carrier with a washing solution containing at least one of the potassium iodide, urea, and guanidine after the step (b), (d) washing off the washing solution of the step (c) remaining in the insoluble carrier from the insoluble carrier, and (e) amplifying the labeling substance of the complex trapped in the reaction site.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: July 18, 2017
    Assignee: FUJIFILM Corporation
    Inventors: Atsuhiko Wada, Ayumi Era
  • Patent number: 9710596
    Abstract: Provided herein is technology relating to evaluating the state of nucleic acids and particularly, but not exclusively, to methods for measuring variations between DNAs, including differences in methylation and mutation.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: July 18, 2017
    Assignee: EXACT SCIENCES CORPORATION
    Inventor: Graham Lidgard
  • Patent number: 9701946
    Abstract: The invention discloses an avian infectious bronchitis virus purification method. The method uses ordinary avian embryo which was affected by avian bronchitis virus. Using the combination of centrifugation, ultrafiltration, concentration, molecular sieve chromatography and ultrafiltration method can effectively remove miscellaneous protein in embryo-derived infectious bronchitis virus antigen, high virus recovery, and have no effect on the activity of avian infectious bronchitis virus. The avian infectious bronchitis virus purified by this method can be directly used in the preparation of avian infectious bronchitis virus vaccine.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: July 11, 2017
    Assignees: Zhaoqing Dahuanong Biological Medicine Co., Ltd, South China Agricultural University
    Inventors: Ruiai Chen, Jiahua Xu, Xinqiu Wang, Dongxia Zhang, Beibei Sun, Xiaoyu Xie, Changbao Ren
  • Patent number: 9701943
    Abstract: The present invention relates to a genetic variant of CMV, said genetic variant lacking intron 2 of the IE region of CMV (CMV IE?i2) The present invention also relates to various uses of this genetic variant as well as RNA splice variants transcribed therefrom, and proteins expressed from the RNA splice variants, such as in the diagnosis of a CMV related cancer disease, and identification of individuals at risk of developing cancer or risk of transferring the CMV IE?i2 virus with a human sample and prevention and treatment through targeting of unique CMV IE proteins for immunotherapy and vaccination.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: July 11, 2017
    Inventor: Cecilia Nauclér
  • Patent number: 9702005
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: July 11, 2017
    Assignee: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph John Sasadeusz, Peter William Angus, William Sievert
  • Patent number: 9702885
    Abstract: The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a hexamer of a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing the gliadin fusion protein on the solid support. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: July 11, 2017
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Roger Walker, Yabin Lu, Urvee Desai, Daming Shan
  • Patent number: 9702017
    Abstract: A method of simultaneously amplifying genotypes 1, 2, 3 and/or 4 of HEV is disclosed comprising amplifying the genotypes 1, 2, 3 and/or 4 of HEV with one single none-degenerate forward primer partially overlapping the 5?UTR region of HEV and at least one reverse primer. Also disclosed are related methods comprising a probe, and kits for the detection of genotypes 1, 2, 3 and/or 4 of HEV.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: July 11, 2017
    Inventors: Hermann Leying, Thomas W. Myers, Nicolas Newton, Eberhard Russmann, Joseph San Filippo, Nancy Schoenbrunner, Heike Wilts, Xiaoning Wu, Karen K. Y. Young, Dirk Zimmermann
  • Patent number: 9695421
    Abstract: The present invention relates to a dengue virus-specific siRNA, a double-stranded oligo RNA structure comprising the siRNA, and a composition for inhibiting dengue virus replication, which comprises the same, in which the double-stranded oligo RNA structure comprises a hydrophilic compound and hydrophobic compound conjugated to both ends of the double-stranded RNA (siRNA) by a single covalent bond or a linker-mediated covalent bond so that they will be efficiently delivered into cells, and can be converted into nanoparticles by hydrophobic interactions between the double-stranded oligo RNA structures in an aqueous solution. The siRNA included in the double-stranded oligo RNA structure acts specifically on all dengue virus serotypes. The present invention also relates to a method for preparing the double-stranded oligo RNA structure, and a pharmaceutical composition for preventing or treating dengue virus infection, which comprises the double-stranded oligo RNA structure.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: July 4, 2017
    Assignee: BIONEER CORPORATION
    Inventors: Joo Sung Yang, Woo Seok Kim, Soon Ja Choi, Han Oh Park
  • Patent number: 9688754
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 27, 2017
    Assignee: ALDER BIOPHARMACEUTICALS, INC.
    Inventors: Andrew Lawrence Feldhaus, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
  • Patent number: 9689023
    Abstract: This invention relates to methods for molecular detection, particularly to methods utilizing target-specific molecular probes. In exemplary embodiments, target-specific molecular probes include single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) aptamers. In general, the molecular probe may bind with relatively high specificity to a given target. In one aspect, a method for molecular detection comprises a molecular probe paired to a reporter molecule wherein the molecular probe impairs the amplification of the reporter molecule in the absence of the target molecule.
    Type: Grant
    Filed: September 25, 2011
    Date of Patent: June 27, 2017
    Assignee: BioTex, Inc.
    Inventors: George Jackson, Christopher Quan
  • Patent number: 9682106
    Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: June 20, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Noriyuki Kasahara, Robert H. Schiestl, Katrin Hacke, Akos Szakmary, Gay M. Crooks
  • Patent number: 9683233
    Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5?UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3?UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: June 20, 2017
    Assignee: CureVac AG
    Inventor: Andreas Thess
  • Patent number: 9682109
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: June 20, 2017
    Assignee: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Peter William Angus
  • Patent number: 9683269
    Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: June 20, 2017
    Assignees: Hvidovre Hospital, The United States of America, As Represented by the Secretary, Department of Health and Human Services
    Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
  • Patent number: 9677120
    Abstract: This document provides methods and materials for detecting target nucleic acid. For example, methods and materials for detecting the presence or absence of target nucleic acid, methods and materials for detecting the amount of target nucleic acid present within a sample, kits for detecting the presence or absence of target nucleic acid, kits for detecting the amount of target nucleic acid present within a sample, and methods for making such kits are provided.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: June 13, 2017
    Assignee: Cascade Biosystems, Inc.
    Inventors: Kenneth D. Smith, Nina Yazvenko, Mariya Smit
  • Patent number: 9675688
    Abstract: A method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: June 13, 2017
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: David M. Koelle, Zhi Liu, Lawrence Corey
  • Patent number: 9671402
    Abstract: Methods, compositions, and kits for performing analyte detection in a lateral flow assay.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: June 6, 2017
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Clayton McKee
  • Patent number: 9670529
    Abstract: Described herein is a method for adding a counter sequence to the individual polynucleotide molecules of an initial nucleic acid sample. After addition of the counter sequence, the sample may be amplified and the number of initial target molecules in the sample can be estimated by counting the number of counter sequences associated with the amplified target molecules.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: June 6, 2017
    Assignee: POPULATION GENETICS TECHNOLOGIES LTD.
    Inventors: Robert Osborne, James Casbon, Andreas Claas, Gi Mikawa, Esther Musgrave-Brown
  • Patent number: 9663834
    Abstract: Provided are methods and compositions useful for detecting viral infection or contamination in a biological sample.
    Type: Grant
    Filed: July 16, 2011
    Date of Patent: May 30, 2017
    Assignee: Tocagen Inc.
    Inventors: Douglas J. Jolly, Omar Perez, Amy Lin
  • Patent number: 9664597
    Abstract: A liquid collection device is provided. The device includes an input conduit, an output conduit, a plurality of product collection containers, and a valve block. The input and output conduits are connectable to a liquid processing line. The valve block has a valve block input in fluid communication with the input conduit, a valve block output in fluid communication with the output conduit, and a plurality of valves. The valves correspond in number to product collection containers and each valve places the input conduit in liquid communication with a different one of the product collection containers. An automated liquid collection workstation for use with the liquid collection device and a method of automatically collecting liquid from a processing line or vessel are also provided.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: May 30, 2017
    Assignee: ALFA WASSERMANN, INC.
    Inventor: Jan Hofman
  • Patent number: 9663779
    Abstract: The present invention relates to a method for purifying nucleic acids from a sample containing nucleic acids, the method comprising at least the following steps: a. bringing the sample containing nucleic acids into contact with a nucleic acid binding phase comprising protonatable groups, wherein the protonatable groups have a pKs value of 9 to 12; b. binding the nucleic acids to the nucleic acid phase at a pH (binding pH) that is at least one pH unit less than the pKs value of at least one of the protonatable groups; c. eluting the nucleic acids at a pH greater than the binding pH but at least one pH unit less than the pKs value of at least one of the protonatable groups. Also disclosed are corresponding kits and nucleic acid binding phases that can be used for purifying nucleic acids.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: May 30, 2017
    Assignee: QIAGEN GMBH
    Inventors: Roland Fabis, Jan Petzel, Sabine Scheltinga
  • Patent number: 9650406
    Abstract: The present invention relates generally to methods of sequencing of polynucleotides and compounds, compositions and kits useful for sequencing of polynucleotides. The chemical compounds include nucleotide and nucleoside analogs which possess a blocking group covalently attached to the 3? hydroxyl of the sugar moiety. The blocking group may optionally be additionally covalently attached to a linker and/or detectable label. The nucleotide analogs may be ribonucleotide or deoxyribonucleotide analogs. Methods include incorporation of the reversible terminator molecules into growing polynucleotide strands by polymerase enzymes, such as in single base sequencing methodologies utilizing sequential reversible termination techniques.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: May 16, 2017
    Assignee: CENTRILLION TECHNOLOGY HOLDINGS CORPORATION
    Inventors: Wei Zhou, Glenn McGall, Moti Jain, Rui Mei
  • Patent number: 9650665
    Abstract: The present invention is generally drawn to a novel method and a kit for detecting nucleotide variations by a PTOCE (PTO Cleavage and Extension) assay with PTO-NV. Furthermore, the present invention is directed to a novel method and a kit for detecting a nucleotide variation on a target nucleic acid sequence by a PTOCE assay with PTO-NV having a non-base paring moiety.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: May 16, 2017
    Assignee: SEEGENE, INC.
    Inventors: Jong Yoon Chun, Young Jo Lee
  • Patent number: 9651568
    Abstract: An operating and reading instrument for performing an assay employing a portable microfluidic assay cartridge, the instrument comprising a translatable table under automated control, the translatable table carrying a receiving region for the portable cartridge and carrying a port system connectable to the cartridge that includes at least one remotely automated valve carried by the translatable table, the valve arranged to apply pressurized flowable substance at selected times to the cartridge while the cartridge is on the translatable table.
    Type: Grant
    Filed: September 6, 2014
    Date of Patent: May 16, 2017
    Assignee: CyVek, Inc.
    Inventors: Martin A. Putnam, Jeffrey T. Branciforte, Charles O. Stanwood
  • Patent number: 9644187
    Abstract: The purity and titer of virus stocks used for virus clearance studies have a significant influence on study outcome, and impact how well the scale-down model represents the production-scale process. Impurities in virus stocks are particularly important in the testing of small virus retentive filters because these impurities may cause a filter to foul prematurely, leading to underestimation of the true throughput capability of the filter and consequent inappropriate sizing of the production scale unit. In addition, impurities can also affect the levels of virus clearance observed by altering the fouling mechanisms and subsequent fluid passage through the virus filter. Described herein are methods for making, producing and using high purity virus stocks having high titer.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: May 9, 2017
    Assignee: EMD Millipore Corporation
    Inventors: Damon R. Asher, Amanda B. Katz, Navid Z. Khan, Ushma Mehta
  • Patent number: 9637780
    Abstract: A hot start enzyme composition is described that includes a hot start nuclease, a nucleic acid polymerase, and a substantially double-stranded oligonucleotide that inhibits the catalytic activity of the nucleic acid polymerase at temperatures lower than the melting temperature of the oligonucleotide.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: May 2, 2017
    Assignee: Hanwha Techwin Co., Ltd.
    Inventors: Win D. Cheung, Jason A. Opdyke
  • Patent number: 9637776
    Abstract: This disclosure features methods of identifying an organism. The methods include: (a) obtaining a nucleic acid sample from an organism; (b) imaging said nucleic acid; (c) obtaining a restriction map of said nucleic acid; and (d) correlating the restriction map of said nucleic acid with a restriction map database, thereby identifying the organism.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: May 2, 2017
    Assignee: OpGen, Inc.
    Inventor: Adam M. Briska
  • Patent number: 9632101
    Abstract: A system for processing samples by a robotic platform has a tray that defines a well defining a drain. The well has a bottom surface, an access port in fluid communication with the drain, and an insert adapted to be received in the well. The insert has a bottom wall and a side wall. At least one of the bottom wall and the side wall define a plurality of openings, such that an interior of the insert is in fluid communication with the well when the insert is inserted into the well.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: April 25, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Rostislav Chernomorsky, Nicholas Gale, Sam Cichon
  • Patent number: 9631243
    Abstract: The disclosure relates to methods and compositions for detecting the presence of Prototype and/or Archetype JC virus in a biological sample from a subject. In some embodiments, the methods include amplifying and detecting a first nucleic acid sequence unique to Archetype JC virus in a biological sample, and a second nucleic acid sequence common to both Archetype and Prototype JC virus in the biological sample. In several embodiments, the methods can be used to identify JC virus in a biological sample from a subject at risk for progressive multifocal leukoencephalopathy. Compositions and kits for use in the disclosed methods are also provided.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 25, 2017
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Eugene Major, Caroline Ryschkewitsch
  • Patent number: 9631220
    Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: April 25, 2017
    Assignee: Janssen Diagnostics BVBA
    Inventors: Kurt Van Baelen, Lieven Jozef Stuyver, Kevin Karel Florentina Arien
  • Patent number: 9624511
    Abstract: Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: April 18, 2017
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Harald zur Hausen, Ethel-Michele de Villiers